MOLBIO DIAGNOSTICS LIMITED

BSE: MOLBIO544866ISIN INE869T01028

Healthcare
Medical Equipment & Supplies
BSE IPO

BSE listing

Share price

₹1,312.65-48.75 (-3.58%)

as of 16 Sep 2026

52W high: ₹1,686.50
52W low: ₹925.80
Off 52W high: -22.17%
1M return: +26.67%
3M return: —
6M return: —
1Y return: —
20D avg volume: 4,29,620
50 DMA: —
200 DMA: —

Key ratios Consolidated

Market cap: ₹15,127 Cr
Current price: ₹1,312.65
52W high / low: ₹1,686.50 / ₹925.80
Face value: ₹1.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: —
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: —
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: —

About

In plain English

Molbio Diagnostics Ltd is a company that recently listed its shares on the stock exchange. Based on its name, it likely operates in the medical diagnostics field, developing tests and equipment to detect diseases. However, the provided source materials—mainly board meeting outcomes and listing announcements—do not contain any details about its specific products, target customers, or how it operates in practice. Without concrete information, it is not possible to give a vivid example or name a real use case. The only confirmed event is that the company's equity shares were listed on August 17, 2026.

AI-generated summary, written from the company's own filings and disclosures. Every figure elsewhere on this page comes from exchange data, not from a model. See our editorial standards. Generated 6 Sep 2026.

Financials

Metric	Q1 FY27
Income statement
	408.38
	3.10
	335.57
	131.47
	6.26
	45.92
	10.70
	17.07
	112.19
	75.91
	0.00
	75.91
	23.16
	52.74
	5.21
Key metrics
	103.68
	25.40%
	12.90%

Metric	Q1 FY27
Income statement
	399.38
	1.37
	324.82
	126.72
	6.09
	24.76
	8.66
	8.42
	138.74
	75.92
	0.00
	75.92
	19.30
	56.63
	5.02
Key metrics
	93.00
	23.30%
	14.20%

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 14 Aug 2026

Promoter holding: 41.29%

Holder	Type	Holding	Previous	Change
EXXORA TRADING LLP	Promoter	37.05%	—	—
BUSINESS EXCELLENCE TRUST III - INDIA BUSINESS EXC	Public	11.52%	—	—
V-SCIENCES INVESTMENTS PTE LTD	Public	8.74%	—	—
GOPALKRISHNA MANGALORE KINI	Public	5.61%	—	—
GOPALAKRISHNA SAMPATHGIRI	Public	4.52%	—	—
JAVAGAL GURU DUTT	Public	4.48%	—	—
CHANDRASEKHAR BHASKARAN NAIR	Promoter	4.24%	—	—
USHA RANI M A	Public	2.45%	—	—
SANGEETHA MANGALORE KINI	Public	2.26%	—	—
ROHIT MULLANGI ASHOK KUMAR	Public	1.45%	—	—
SHRUTHI G KINI	Public	1.09%	—	—
Sarada Natarajan	Promoter Group	0.00%	—	—
Indalia Medical Devices Private Limited	Promoter Group	0.00%	—	—
Coreintegra Consulting Services Limited	Promoter Group	0.00%	—	—
In-Med Prognostics Inc	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Pursuant to Regulation 30 of the SEBI(LODR),2015, Please find attached herewith the Transcripts of the Earning call held on September 08,2026 in relation to the Fianncial Results for the ....12 Sep 2026 · Company Update / Earnings Call Transcript
Intimation of Change of Corporate Identification Number (CIN) of the company.9 Sep 2026 · Company Update / General
Audio Recording of Earnings Call for the quarter ended June 30, 2026.8 Sep 2026 · Company Update / Analyst / Investor Meet
Investor Presentation on Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.8 Sep 2026 · Company Update / Investor Presentation
Newspaper advertisments of Un-Audited Financials Results for the quarter ended June 30, 2026.7 Sep 2026 · Company Update / Newspaper Publication
Molbio Diagnostics Limited has informed the Exchange regarding the Press Release for the Quarter ended June 30,2026.7 Sep 2026 · Company Update / Press Release / Media Release
The Board of Directors at their meeting held on Saturday, September 05, 2026 approved the Un-audited Financial Results (Standalone & Consolidated) for the quarter ended on June 30, 20265 Sep 2026 · Board Meeting / Outcome of Board Meeting
Outcome of the Board Meeting held on Saturday, September 05,2026.5 Sep 2026 · Result / Financial Results
Intimation of Earnings Conference Call under Regulation 30 and all other applicable regulations, if any, of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) ....2 Sep 2026 · Company Update / Analyst / Investor Meet
Molbio Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2026 ,inter alia, to consider and approve To consider and approve ....1 Sep 2026 · Board Meeting / Board Meeting
Outcome of Board Meeting held on August 27, 2026, as per Reg 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').27 Aug 2026 · Others / Outcome without intimation
Intimation of Closure Trading Window as per SEBI (Prohibition of Insider Trading) Regulations, 201520 Aug 2026 · Insider Trading / SAST / Closure of Trading Window
Trading Members of the Exchange are hereby informed that effective from August 17, 2026, the Equity Shares of Molbio Diagnostics Ltd (Scrip Code: 544866) are listed and admitted to dealings ....17 Aug 2026 · New Listing / New Listing

Board meetings

5 Sep 2026 Board Meeting - Financial Results